LENZ Therapeutics (LENZ) Cash from Operations (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Cash from Operations of 33582000.0 for Q1 2026, down 109.25% year-over-year from 363178920.49 in Q1 2025, and down 1.69% quarter-over-quarter from 33025000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Cash from Operations (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Cash from Operations for 7 consecutive years, with 33582000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 109.25% year-over-year to 33582000.0; the TTM figure through Mar 2026 stood at 86703000.0 (down 68.35% YoY), while the FY2025 annual figure was 69170000.0, down 16.47% from the prior year.
- Cash from Operations declined to 33582000.0 in Q1 2026 per LENZ's latest filing, from 33025000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8588000.0 in Q3 2025 and bottomed at 33582000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 18264882.35 across 5 years, with a median of 16049000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 56.71% — and 2025, when it plunged 263.79%.
- LENZ Therapeutics' Cash from Operations stood at 22429000.0 in 2022, then increased by 6.5% to 20970000.0 in 2023, then soared by 56.71% to 9078000.0 in 2024, then slumped by 263.79% to 33025000.0 in 2025, then retreated by 1.69% to 33582000.0 in 2026.
- Business Quant data shows LENZ's Cash from Operations at 33582000.0 in Q1 2026, 33025000.0 in Q4 2025, and 8588000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | -38.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.71 Mn |
| Jun 30, 2026 | -38.71 Mn |
| Mar 31, 2026 | -33.58 Mn |
| Mar 31, 2026 | -33.58 Mn |
| Dec 31, 2025 | -33.03 Mn |
| Dec 31, 2025 | -33.03 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -11.51 Mn |
| Jun 30, 2025 | -11.51 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Dec 31, 2024 | -9.08 Mn |
| Dec 31, 2024 | -9.08 Mn |
| Sep 30, 2024 | -10.58 Mn |
| Sep 30, 2024 | -10.58 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Mar 31, 2024 | -23.94 Mn |